These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 24668729

  • 1. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients.
    John K, Dieterlen MT, Tarnok A, Garbade J, Bittner HB, Mohr FW, Barten MJ.
    Cytometry B Clin Cytom; 2014 Sep; 86(5):362-7. PubMed ID: 24668729
    [Abstract] [Full Text] [Related]

  • 2. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 20; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 4. Impaired circulating dendritic cell reconstitution identifies rejecting recipients after clinical heart transplantation independent of rejection therapy.
    Athanassopoulos P, Vaessen LM, Balk AH, Takkenberg JJ, Maat AP, Weimar W, Bogers AJ.
    Eur J Cardiothorac Surg; 2005 May 20; 27(5):783-9. PubMed ID: 15848314
    [Abstract] [Full Text] [Related]

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 15; 36(8):2384-5. PubMed ID: 15561256
    [Abstract] [Full Text] [Related]

  • 7. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ, Rossi AF, Courtney M, Gelb BD.
    J Heart Lung Transplant; 1998 Dec 15; 17(12):1195-200. PubMed ID: 9883760
    [Abstract] [Full Text] [Related]

  • 8. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Dec 15; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 9. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
    Sánchez-Lázaro IJ, Almenar L, Martínez-Dolz L, Buendía-Fuentes F, Agüero J, Navarro-Manchón J, Vicente JL, Salvador A.
    Clin Transplant; 2011 Dec 15; 25(4):606-13. PubMed ID: 20682020
    [Abstract] [Full Text] [Related]

  • 10. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

  • 11. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.
    Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2014 Jul 15; 8():1307-14. PubMed ID: 25246772
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.
    Pediatr Transplant; 1999 Feb 15; 3(1):22-6. PubMed ID: 10359027
    [Abstract] [Full Text] [Related]

  • 13. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
    Fuchs U, Klein S, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Ann Transplant; 2014 Jun 23; 19():300-4. PubMed ID: 24953848
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 23; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 15. Peripheral blood dendritic cells in human end-stage heart failure and the early post-transplant period: evidence for systemic Th1 immune responses.
    Athanassopoulos P, Vaessen LM, Maat AP, Balk AH, Weimar W, Bogers AJ.
    Eur J Cardiothorac Surg; 2004 Apr 23; 25(4):619-26. PubMed ID: 15037281
    [Abstract] [Full Text] [Related]

  • 16. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies.
    Töz H, Sen S, Seziş M, Duman S, Ozkahya M, Ozbek S, Hoşcoşkun C, Atabay G, Ok E.
    Transplant Proc; 2004 Apr 23; 36(1):134-6. PubMed ID: 15013324
    [Abstract] [Full Text] [Related]

  • 17. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine.
    Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, Krom RA.
    Transplantation; 1996 Dec 15; 62(11):1588-92. PubMed ID: 8970613
    [Abstract] [Full Text] [Related]

  • 18. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
    Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M.
    Transplantation; 2003 Mar 27; 75(6):844-51. PubMed ID: 12660513
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 20. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct 27; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.